We look forward to seeing you at the following events in 2016. Check back regularly for updates on medical meetings, new podcasts, webinars and more.
Coastal Cardiac & Vascular Conference - February 13, 2016; Cambridge, MD
Heart Rhythm Society 37th Annual Scientific Sessions - May 4-7, 2016; San Francisco, CASee all upcoming events
David B. Camp
Co-Founder, Chief Executive Officer and Chairman of the Board, CorMatrix Cardiovascular
David Camp is the Chief Executive Officer and Chairman of the Board of CorMatrix. David is a co-founder of the company. He has an extensive history as an entrepreneurial executive in the medical device field, with a particular focus on cardiovascular device markets. He has a proven and successful track record of introducing new technologies, developing successful sales distribution networks and establishing loyal physician user networks. David has more than 29 years experience in the medical device field including working with St. Jude Medical, Medtronic, SciMed Life Systems (purchased by Boston Scientific), American Edwards Corp. (AME), U.S. Surgical, and Smith Kline Pharmaceutical.
Notably, David was one of the original sales and marketing team members responsible for the launch of the angiographic division of AME. He was also one of the original four sales representatives hired in 1987 to launch angioplasty technology nationwide for SciMed Life Systems. During his nine year tenure with SciMed, his team was responsible for growing sales from zero to over $350 million.
Robert G. Matheny, MD
Co-Founder, Chief Scientific Officer and Scientific Advisory Board Director, CorMatrix Cardiovascular
Dr. Robert Matheny is the Chief Scientific Officer for CorMatrix Cardiovascular. As a Cardiothoracic surgeon and distinguished pioneer of minimally invasive cardiac surgical procedures, Dr. Matheny has worked with ECM materials for cardiovascular applications since 1993 and is co-inventor on several of the Purdue ECM patents.
Dr. Matheny did his undergraduate studies at the University of Oklahoma and Baylor University, completed his MD at the University of Texas, performed his Surgical residency at Scott and White Hospital, Texas A&M University, and completed his Cardiothoracic fellowship at Ohio State University. He is certified by the American Board of Surgery and the American Board of Thoracic Surgery and is a Fellow of the American College of Surgeons.
Dr. Matheny worked with a number of medical device companies as a consultant in off-pump heart surgery, atrial fibrillation, robotics and ventricular support devices, including CardioThoracic Systems, Medtronic, Embolex, Amed Systems, Guidant, AFx and Corazon. He published numerous articles and chapters and holds patents for many medical devices.
John C. Thomas, Jr.
Chief Financial Officer and Secretary, CorMatrix Cardiovascular
John Thomas is the Chief Financial Officer of CorMatrix and has been with the Company since its inception. John brings a wealth of experience working with start-up medical device companies and has more than 34 years experience in a variety of financial and accounting positions, with the last 23 years spent in the medical, pharmaceutical and device fields.
He has extensive experience in the capital markets, having been in the role of CFO for eight companies that went public during his tenure, six of those being in the medical space (Cytrx Corporation, Cytrx Biopool, Medicis Pharmaceutical, EntreMed, MiMedx Group, and Dara BioSciences).
John is a graduate of the University of Virginia and a Certified Public Accountant (CPA).
Andrew M. Green
Executive Vice President of Operations, CorMatrix Cardiovascular
Andrew (Drew) Green is the Executive Vice President of Operations. Drew has 20 years of experience in regulatory, clinical and quality for medical devices. Prior to CorMatrix, Drew was the VP of Regulatory and Clinical Affairs at Halscion, Inc., a private company developing an injectable hydrogel bioscaffold for dermal applications.
Drew's previous experience also includes the position of President and CEO for Oncologix Tech, Inc., a publicly traded medical device company developing an interventional treatment for metastatic liver cancer; a principal in NeoMedica, LLC, a consulting group that specialized in medical device consulting for clients that included early stage ventures dealing with class I, II, and III medical devices. Prior to that, from 1996 to 2005, he was employed by Novaste Corporation (a publicly traded medical device company) with the final position as the corporate officer with responsibility for Regulatory Affairs, Clinical Affairs, Quality Assurance and New Technology.
Drew started his career as a Scientific Reviewer/Biomedical Engineer for the FDA, where he was responsible for the review of scientific, technical, pre-clinical and clinical data submitted in support of the safety and effectiveness of both interventional and general cardiovascular devices.
Drew holds a BS degree in Biological Sciences and an MS degree in Bioengineering, both from Clemson University, where his research focused on characterization and use of materials in a biological environment.
Beecher C. Lewis
Chief Strategic Operations, CorMatrix Cardiovascular
Beecher Lewis is Chief Strategic Operations of CorMatrix. Beecher serves in several strategic rolls with more than 20 years of experience in sales and marketing of medical surgical products. Beecher has a keen understanding of how to build strategic businesses, establish corporate operations and deliver innovative and meaningful technology to physicians.
He held leadership positions at Harbor Medical Devices, Smith & Nephew Richards, Implex Corp. (acquired by Zimmer Holdings, Inc.), Orthopedic BioSystems Ltd. (acquired by Smith & Nephew) and Regeneration Technologies, Inc. where he gained valuable insights into developing key partnerships, setting up initial operations, and expediting the development and introduction of sales and marketing networks.
Beecher also previously served as Director of Sales and Marketing at The Alabama Tissue Center, cardiac division of Regeneration Technologies, Inc., where he established and executed a novel, nationwide and independent distribution network to promote the company's cardiovascular tissues including heart valves, blood vessels and non-valved conduits.